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Objective:  The  exact  association  between  obstructive  sleep  apnea  (OSA)  and  premature  supraventricular
contractions  (PSVCs)  has  not  been  established.
Methods: We  prospectively  performed  polysomnography  together  with  24-hour  Holter  electrocardio-
graphy  in 431  patients  who  were  clinically  suspected  of  having  OSA  and  examined  the  association
between  OSA  severity  and  PSVCs  during  wakefulness  and  sleep.  The  patients  were  classiﬁed  into  4  groups
according  to the  apnea–hypopnea  index  (AHI)  quartiles  (Q1  = patients  with AHI  < 13.8, Q2  = those  with
13.8  ≤ AHI  < 28.8,  Q3  = those  with  28.8  ≤ AHI  <  48.1,  Q4  = those  with  AHI  ≥ 48.1).
Results:  The  number  of PSVCs/hour  during  sleep  differed  signiﬁcantly  among  the  4 groups,  but the  number
of  PSVCs/hour  during  wakefulness  did  not. The  prevalence  of  PSVC  ≥  5/hour  during  sleep  was  signiﬁcantly
higher  in Q4  (21.0%)  than  the  other  3 groups  (Q1, 9.0%;  Q2,  8.0%;  Q3,  6.0%;  all  p  < 0.05  for  Q4),  but  thepnea–hypopnea index prevalence  of  PSVC  ≥  5/hour  during  wakefulness  did  not  differ  among  the  4 groups.  A multivariate  logistic
regression  analysis  showed  that  the highest  AHI  quartile  was  signiﬁcantly  associated  with  PSVC  ≥ 5/hour
during  sleep  (odds  ratio  3.04,  95%  conﬁdence  interval  1.44–6.42,  p = 0.004).
Conclusions:  Severe  OSA  can  cause  PSVCs  during  sleep,  but its effect  appears  not to be  strong.  Further
studies  are  needed  to  clarify  the  clinical  signiﬁcance  of  this  small  but signiﬁcant  increase  in  PSVCs  during
sleep  in severe  OSA  patients.
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Much attention has been recently paid to the association
etween sleep-disordered breathing and cardiovascular diseases
ncluding hypertension, arrhythmias, coronary artery disease, aor-
ic dissection, congestive heart failure, pulmonary hypertension,
nd strokes [1–3]. Obstructive sleep apnea (OSA), which is a
hronic condition characterized by repetitive episodes of upper
irway collapse, apnea, and arousal during sleep, is the most fre-
uent sleep-disordered breathing. The association between OSA
nd premature ventricular contractions has been repeatedly inves-
igated [4–13]. On the other hand, only several investigations
ave been undertaken about the association between OSA and
remature supraventricular contractions (PSVCs) [8–10,12], and
he results of these studies are conﬂicting. It has been demon-
trated that an isolated PSVC can trigger atrial ﬁbrillation and
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supraventricular tachycardia [14,15] and that frequent PSVCs are
associated with increased risks for stroke or death as well as atrial
ﬁbrillation [16,17]. Therefore, it is clinically important to clarify
whether OSA can contribute to the occurrence of PSVCs. In this
study, we prospectively examined the association between OSA
severity and PSVCs during wakefulness as well as sleep in patients
who were clinically suspected of having OSA.
Methods
Subjects
A total of 431 patients (336 males and 95 females, median age 56
years) who were clinically suspected of having OSA  (severe snor-
ing, daytime sleepiness, and witnessed apnea) and who  met  the
inclusion criteria were prospectively enrolled into this study. All
patients underwent full polysomnography together with 24-hour
Holter electrocardiography. The inclusion criteria were aged ≥ 20
years, absence of chronic atrial ﬁbrillation/ﬂutter, no use of antiar-
rhythmic agents, no signs or symptoms of congestive heart failure,
no pacemaker implantation and no treatment of OSA with oral
vier Ltd. All rights reserved.
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ppliance, continuous positive airway pressure, bi-level positive
irway pressure, or adaptive servo-ventilation. Patients with dom-
nantly central sleep apnea (n = 2) and the occurrence of atrial
brillation on the 24-hour Holter electrocardiogram (n = 2) were
xcluded. The study protocol was approved by the ethics commit-
ee of Oita University Hospital, and informed consent was obtained
rom each patient before the study.
olysomnography
Polysomnography was performed using a computerized
ecording system (E-series, Compumedics, Abbotsford, Australia).
his investigation consisted of monitoring of the electro-
ncephalogram, electrooculogram, submental and limb elec-
romyograms, electrocardiogram, thoraco-abdominal excursions
y a piezo belt, oronasal airﬂow by a nasal pressure transducer and
n oronasal thermistor, and the arterial oxyhemoglobin saturation
y transcutaneous pulse oximetry. An obstructive apnea event was
eﬁned as the absence of oronasal airﬂow for ≥10 seconds associ-
ted with continued or increased inspiratory effort. A central apnea
as deﬁned as the absence of oronasal airﬂow for ≥10 seconds
ssociated with an absent inspiratory effort. A hypopnea was
eﬁned as a ≥50% reduction in oronasal airﬂow for ≥10 seconds,
ssociated with a ≥3% fall in arterial oxyhemoglobin saturation or
n arousal. The apnea–hypopnea index (AHI) was calculated as the
ean number of apneas and hypopneas per hour of sleep.
4-Hour  Holter electrocardiography
Together  with overnight polysomnography, 24-hour Holter
lectrocardiography was performed using a digital recorder
ith 3 channels (RAC-3103, Nihon Koden, Tokyo, Japan).
olysomnography and 24-hour Holter electrocardiography were
ime-synchronized. The presence or absence of PSVC ≥ 5/hour dur-
ng wakefulness as well as sleep was assessed. This PSVC cut-off
alue has been used in previous studies investigating the asso-
iation between OSA and PSVCs [8,10,12]. The mean numbers of
SVCs/hour during wakefulness as well as sleep was  also calcu-
ated. Based on the electro-encephalogram, the sleep period was
eﬁned as the period from the starting of sleep to the end of sleep.
tatistical analysis
Continuous data are expressed as the median (ﬁrst-third quar-
iles). The Kruskal–Wallis test with the Scheffe’s post hoc test was
sed for comparisons of continuous data among 4 groups. Compar-
sons of categorical variables were analyzed by the Fisher’s exact
est or chi-square test. The univariate and multivariate logistic
able 1
atient characteristics and polysomnographic data.
Variables Q1 (n = 107) Q2 (n = 108) 
Age (years) 56.0 (41.0–64.0) 62.0 (51.0–70.0
Male  gender 64 (59.8%) 84 (77.8%) 
Body  mass index (kg/m2) 23.3 (21.5–25.8) 24.4 (22.7–26.7
Hypertension 53 (49.5%) 73 (67.6%) 
Dyslipidemia  64 (59.8%) 70 (64.8%) 
Diabetes  14 (13.1%) 25  (23.1%) 
Current  smoker 22 (20.6%) 24 (22.2%) 
Coronary  artery disease 19 (17.8%) 22 (20.4%) 
AHI  6.0 (2.8–9.3) 20.9 (17.5–23.9
Calcium  antagonists 30 (28.0%) 49 (45.4%) 
ACEIs/ARBs  27 (25.2%) 43 (38.9%) 
Beta-blockers 14 (13.1%) 14 (13.0%) 
alues are presented as the median (ﬁrst–third quartiles).
1  = patients with AHI < 13.8; Q2 = those with 13.8 ≤ AHI < 28.8; Q3: those with 28.8 ≤ AH
HI,  apnea–hypopnea index; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotdiology 63 (2014) 69–72
regression  analyses were performed to determine variables asso-
ciated with PSVC ≥ 5/hour during sleep. A value of p < 0.05 was
considered to be statistically signiﬁcant. Statistical analyses were
performed using IBM SPSS Statistics 20 (International Business
Machines, New York, NY, USA).
Results
Of 431 patients, 385 (89.3%) had an AHI ≥ 5. The 431 patients
were classiﬁed into 4 groups according to the AHI quartiles
(Q1 = 107 patients with AHI < 13.8; Q2 = 108 with 13.8 ≤ AHI < 28.8;
Q3 = 108 with 28.8 ≤ AHI < 48.1; Q4 = 108 with AHI ≥ 48.1). The
patient characteristics are shown in Table 1. Age, body mass index,
and the prevalences of male gender, hypertension, diabetes mel-
litus, calcium antagonist use, and angiotensin-converting enzyme
inhibitor or angiotensin receptor blocker use differed signiﬁcantly
among the 4 groups.
The  number of PSVCs/hour during sleep differed signiﬁcantly
among the 4 groups (Q1, 0.4 [0.0–1.2]; Q2, 0.6 [0.2–1.5]; Q3,  0.5
[0.1–1.2]; Q4, 0.9 [0.2–3.1]; p = 0.01), but the number of PSVCs/hour
during wakefulness did not (Q1, 0.6 [0.1–1.3]; Q2,  0.6 [0.2–1.6];
Q3, 0.5 [0.2–1.3]; Q4, 0.6 [0.2–2.4]; p = 0.75). The prevalence of
PSVC ≥ 5/hour during sleep was  signiﬁcantly higher in Q4 (21.0%)
than in the other 3 groups (Q1, 9.0%; Q2, 8.0%; Q3, 6.0%; all p < 0.05
for Q4), but the prevalence of PSVC ≥ 5/hour during wakefulness
did not differ signiﬁcantly among the 4 groups (p = 0.20) (Fig. 1).
The number of PSVCs/hour during sleep and that during
wakefulness differed signiﬁcantly among the 4 groups classi-
ﬁed by the arousal index (ArI) quartiles (A-Q1 = 107 patients
with ArI < 21.2: 0.4 [0.1–0.9]; A-Q2 = 107 with 21.2 ≤ ArI < 31.9:
0.5 [0.1–1.1]; A-Q3 = 109 with 31.9 ≤ ArI < 48.5: 0.6 [0.2–1.6]; A-
Q4 = 108 with ArI ≥ 48.5: 1.0 [0.2–2.6]; p = 0.001, and A-Q1: 0.4
[0.1–1.2]; A-Q2: 0.6 [0.2–1.3]; A-Q3: 0.7 [0.3–2.0]; A-Q4: 0.7
[0.2–2.1]; p = 0.048, respectively). The prevalence of PSVC ≥ 5/hour
during sleep differed signiﬁcantly among the 4 groups (A-Q1, 6.5%;
A-Q2, 4.7%; A-Q3, 11.9%; A-Q4, 17.6%; p < 0.01), and the prevalence
of PSVC ≥ 5/hour during wakefulness tended to differ among the 4
groups (A-Q1, 7.5%; A-Q2, 3.7%; A-Q3, 11.0%; A-Q4, 13.9%; p = 0.05).
The number of PSVCs/hour during sleep and that during wakeful-
ness did not differ signiﬁcantly among the 4 groups classiﬁed by
the lowest SpO2 (L-SpO2) quartiles (L-Q1 = 100 with L-SpO2 < 77%:
0.5 [0.1–2.1]; L-Q2 = 105 with 77% ≤ L-SpO2 < 83%: 0.5 [0.3–1.5]; L-
Q3 = 110 with 83% ≤ L-SpO2 < 88%: 0.6 [0.2–1.6]; L-Q4 = 116 with
L-SpO2 ≥ 88%: 0.4 [0.1–1.5]; p = 0.11, and L-Q1: 0.4 [0.1–1.8]; L-
Q2: 0.6 [0.2–1.6]; L-Q3: 0.7 [0.3–1.7]; L-Q4: 0.6 [0.1–1.3]; p = 0.30,
respectively). The prevalence of PSVC ≥ 5/hour during sleep tended
to differ among the 4 groups (L-Q1, 16.0%; L-Q2, 11.4%; L-Q3, 5.5%;
L-Q4, 8.6%, p = 0.08), but the prevalence of PSVC ≥ 5/hour during
Q3 (n = 108) Q4 (n = 108) p-Value
) 62.0 (50.3–70.0) 54.0 (44.0–66.8) <0.001
92 (85.2%) 96 (88.9%) <0.001
) 25.5 (23.6–28.7) 28.4 (25.3–32.7) <0.001
76 (70.4%) 74 (68.5%) 0.004
78 (72.2%) 79 (73.1%) 0.11
33 (30.6%) 33 (30.6%) 0.01
17 (15.7%) 23 (21.3%) 0.65
16 (14.8%) 8 (7.4%) 0.05
) 36.5 (31.6–42.1) 65.3 (58.4–81.9) <0.001
49 (45.4%) 52 (48.1%) 0.01
50 (46.3%) 43 (39.8%) 0.01
14 (13.0%) 16 (14.8%) 0.97
I < 48.1; Q4: those with AHI ≥ 48.1.
ensin receptor blocker.
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Pig. 1. Prevalence of premature supraventricular contractions ≥ 5/hour during wake
ith  AHI < 13.8; Q2 = those with 13.8 ≤ AHI < 28.8; Q3 = those with 28.8 ≤ AHI < 48.1
akefulness did not differ signiﬁcantly among the 4 groups (L-Q1,
.0%; L-Q2, 13.3%; L-Q3, 6.4%; L-Q4, 7.8%; p = 0.32).
A univariate logistic regression analysis showed that the high-
st AHI quartile was signiﬁcantly associated with PSVC ≥ 5/hour
uring sleep (odds ratio 3.15, 95% conﬁdence interval 1.66–5.96,
 < 0.001) (Table 2). When we performed a multivariate logistic
egression analysis (forward selection method) including age, male
ender, body mass index, hypertension, diabetes mellitus, cur-
ent smoking, coronary artery disease, the highest AHI quartile,
enin–angiotensin system inhibitor (angiotensin-enzyme inhibitor
r angiotensin receptor blocker) use and beta-blocker use as
xplanatory variables, the highest AHI quartile was  signiﬁcantly
ssociated with PSVC ≥ 5/hour during sleep (odds ratio 3.04, 95%
onﬁdence interval 1.44–6.42, p = 0.004) (Table 2).
iscussion
There are 3 large-population studies to investigate the asso-
iation between sleep-disordered breathing or OSA and PSVCs
8,10,12]. The Sleep Heart Health Study showed that PSVC ≥ 5/hour
uring sleep was more common in 228 subjects with sleep-
isordered breathing [respiratory disturbance index (the mean
umber of apneas and hypopneas per hour of sleep assessed by
ortable monitoring) ≥ 30] than in 338 without sleep-disordered
reathing (respiratory disturbance index < 5) (33.8% vs 24.3%,
 = 0.001) [8]. However, that study did not analyze whether sleep-
isordered breathing was independently associated with PSVCs
uring sleep. In addition, it did not examine the association
etween sleep-disordered breathing and PSVCs during wakeful-
ess. In the MrOS study involving 2911 men  aged ≥65 years, the
revalence of PSVC ≥ 5/hour during sleep did not differ signiﬁ-
antly among the 4 groups classiﬁed by the quartiles of respiratory
isturbance index [10]. However, that study included only men
able 2
nivariate and multivariate logistic regression analyses to determine variables associated
Variables Univariate 
Odds ratio (95% conﬁdence interval) 
Age (years) 1.00 (0.98–1.03) 
Male  gender 1.11 (0.51–2.40) 
Body  mass index (kg/m2) 1.03 (0.97–1.09) 
Hypertension  1.23 (0.63–2.39) 
Diabetes  1.19 (0.59–2.40) 
Current  smoker 0.73 (0.32–1.71) 
Coronary  artery disease 1.07 (0.46–2.52)
Highest  AHI quartile 3.15 (1.66–5.96) 
ACEIs/ARBs  0.84 (0.44–1.63) 
Beta-blockers  1.25 (0.53–2.95) 
SVC, premature supraventricular contraction; AHI, apnea–hypopnea index; ACEI, angiots and that during sleep among 4 groups classiﬁed by the AHI  quartiles. Q1 = patients
hose with AHI ≥ 48.1. *p < 0.05 vs Q4. AHI, apnea–hypopnea index.
aged  ≥65 years, and subjects with central sleep apnea were also
included. In a study involving 486 middle-aged (30–65 years) sub-
jects, Namtvedt et al. did not ﬁnd signiﬁcant differences in the
prevalences of PSVC ≥ 5/hour during daytime as well as nighttime
between subjects with OSA (AHI ≥ 5) and those without it (41.7% vs
48.4% and 49.4% vs 49.8%, respectively) [12]. However, in that study,
OSA was  deﬁned as AHI ≥ 5, and only 14.8% of the subjects had
severe OSA (AHI ≥ 30). In addition, the deﬁnitions of daytime and
nighttime were not described. Thus, the exact association between
OSA severity and PSVCs during wakefulness as well as sleep has not
yet been established.
In  the present study, the prevalence of PSVC ≥ 5/hour during
sleep was  signiﬁcantly higher in patients with the highest AHI
quartile than in the other 3 groups of patients, and the number of
PSVCs/hour during sleep differed signiﬁcantly among the 4 groups.
Furthermore, the univariate logistic regression analysis showed
that the highest AHI quartile was signiﬁcantly associated with
PSVC ≥ 5/hour during sleep, and the multivariate logistic regression
analysis selected the highest AHI quartile as the only independent
variable associated with PSVC ≥ 5/hour during sleep. These results
suggest that OSA can contribute to the occurrence of PSVCs during
sleep and that there may  be a threshold effect on the association
between OSA severity and the occurrence of PSVCs during sleep.
On the other hand, the prevalence of PSVCs during wakefulness
and the number of PSVCs/hour during wakefulness did not differ
signiﬁcantly among the 4 groups classiﬁed by the AHI quartiles.
However, since the prevalence of PSVC ≥ 5/hour during wakeful-
ness tended to be higher in patients with the highest AHI, the
association between OSA severity and PSVCs during wakefulness
awaits further investigation.
In  the present study, the number of PSVCs/hour during sleep
was only 0.9 (0.2–3.1) in patients with the highest AHI  quartile.
This result suggests that the effect of OSA on the occurrence of
 with PSVC ≥ 5/hour during sleep.
Stepwise multivariate








<0.001 3.04 (1.44–6.42) 0.004
0.61
0.62
ensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker.
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SVCs during sleep is not strong. It is unclear whether such low fre-
uency PSVCs during sleep have any clinical signiﬁcance in patients
ith OSA. However, considering that an isolated PSVC can trig-
er atrial ﬁbrillation [14,15] and that nocturnal atrial ﬁbrillation
s more common in OSA patients than in non-OSA subjects [8,11],
he occurrence of PSVCs during sleep might contribute to the future
ccurrence of nocturnal atrial ﬁbrillation in patients with OSA. Fur-
her studies are therefore needed to clarify the association between
he presence or number of PSVCs during sleep and future nocturnal
trial ﬁbrillation in patients with OSA.
The possible mechanisms by which OSA causes PSVCs are as fol-
ows. First, OSA-related hypoxia, hypercapnia, loss of lung inﬂation,
nd arousal can all activate the sympathetic nervous system, which
an cause PSVCs through abnormal automaticity and triggered
ctivity based on the increase of the intracellular Ca2+ concen-
ration [18]. Also, sympathetic nervous activation shortens the
uration of the action potential by the increase of delayed rectiﬁer
+ current [19,20], which can lead to a shortening of the effective
efractory period and thereby the occurrence of PSVCs. Second,
xcessively negative intrathoracic pressure against the occluded
pper airway during an obstructive event stretches the atrial mus-
le and the pulmonary vein, leading to the occurrence of PSVCs
hough the activation of the L-type Ca2+ channel and the tran-
ient receptor potential channels and a resultant increase in the
ntracellular Ca2+ concentration [21–23].
The present study has several limitations. First, the study
ncluded a selected cohort of patients who were clinically sus-
ected of having OSA. Therefore, the ﬁndings of the present study
ay not be applicable to a general population with OSA. Second,
he present study excluded patients with antiarrhythmic agent use
r the occurrence of atrial ﬁbrillation/ﬂutter at baseline or on the
4-hour Holter electrocardiogram, who would potentially have a
arger number of PSVCs than those without it. Therefore, a posi-
ive association between OSA and PSVCs during sleep indicated by
he present study might have been underestimated. Third, 24-hour
olter electrocardiographic ﬁndings may  not accurately reﬂect the
ctual severity of PSVCs, because there is day-to-day variability in
he frequency of PSVCs. Fourth, we did not analyze the association
etween timing of the occurrence of PSVCs and OSA events. The
lariﬁcation of this association would provide important informa-
ion about the cause–effect relationship between OSA and PSVCs
uring sleep.
In  conclusion, severe OSA can cause PSVCs during sleep, but its
ffect appears not to be strong. Further studies are needed to clar-
fy the clinical signiﬁcance of this small but signiﬁcant increase in
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